Study of Adze1.C for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have advanced melanoma (Stage IIIB or IV) that cannot be removed by surgery and has not responded to standard treatments.
- You have at least one tumor or lymph node that can be directly injected with the study drug.
- You must be in good general health (ECOG score 0 or 1).
- You cannot have had other oncolytic virus treatments in the last 2 months or any adenovirus treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests a virus therapy (oncolytic adenovirus) injected directly into melanoma tumors, including those in the brain. It aims to see if the virus can safely shrink tumors and improve the immune response.
This Phase 2 study tests crizanlizumab alone or with nivolumab to treat people with certain brain tumors that have spread to the brain (melanoma) or glioblastoma. The goal is to see whether this approach can control the disease and improve outcomes.
This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.